Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
CC transcript
SANTARUS INC (SNTS) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/17/2015 SC 13G WATER ISLAND CAPITAL LLC reports a 0% stake in SANTARUS INC.
02/14/2014 SC 13G/A SAC Capital Advisors LP reports a 0% stake in SANTARUS, INC.
02/14/2014 SC 13G/A Visium Asset Management, LP reports a 0% stake in Santarus, Inc.
02/14/2014 SC 13G WATER ISLAND CAPITAL LLC reports a 7.4% stake in SANTARUS INC.
01/02/2014 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "Third Amended and Restated Certificate of Incorporation of Santarus, Inc",
"Second Amended and Restated Bylaws of Santarus, Inc"
01/02/2014 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/03/2013 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements
12/03/2013 SC TO-T Form SC TO-T - Tender offer statement by Third Party
12/02/2013 SC14D9C Form SC14D9C - Written communication relating to third party tender offer
11/12/2013 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
11/12/2013 8-K Quarterly results
11/08/2013 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
11/08/2013 SC14D9C Form SC14D9C - Written communication relating to third party tender offer
11/07/2013 10-Q Quarterly Report for the period ended September 30, 2013
11/07/2013 SC14D9C Form SC14D9C - Written communication relating to third party tender offer
11/07/2013 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
11/07/2013 8-K Quarterly results
Docs: "Agreement and Plan of Merger, by and among Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Willow Acquisition Sub Corporation and Santarus, Inc",
"Tender and Support Agreement, by and among Salix Pharmaceuticals, Ltd., Willow Acquisition Sub Corporation and certain stockholders of Santarus, Inc",
"Amendment to Amended and Restated Bylaws of Santarus, Inc",
"SANTARUS REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Total revenues of $98.8 million grew 81% over prior year period Non-GAAP adjusted earnings of $35.6 million were up 189% over prior year period Santarus cancels conference call previously scheduled for 5:00 p.m. Eastern Time today",
"SALIX PHARMACEUTICALS TO ACQUIRE SANTARUS Solidifies Position as Largest U.S. Gastroenterology-Focused Specialty Pharmaceutical Company Provides Salix with an Experienced Specialty Sales Force to Significantly Expand Gastrointestinal Product Sales Increases Commercial Presence in Gastroenterology, Hepatology and Colorectal Surgery Estimated 2013 Pro Forma Total Product Revenue of $1.3 Billion Greatly Increases Scale and Revenue Diversification Expected to be Immediately and Significantly Accretive Expected to Generate Strong EBITDA and Cash from Operations Leading to Rapid Debt Repayment"
11/07/2013 SC 13G/A Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend]
08/06/2013 10-Q Quarterly Report for the period ended June 30, 2013
08/06/2013 8-K Quarterly results
Docs: "SANTARUS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Total revenues of $89.4 million grew 89% over prior year period Raises 2013 financial outlook to include total revenues of $355 million to $360 million, and non-GAAP adjusted earnings of $97 million to $101 million"
06/24/2013 8-K Other Events
06/18/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "SANTARUS AND PHARMING ANNOUNCE FDA ACCEPTANCE FOR REVIEW OF RUCONEST BIOLOGICS LICENSE APPLICATION"
06/12/2013 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans
05/31/2013 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/10/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among Santarus, Inc., Cosmo Technologies Limited and Jefferies LLC",
"Opinion of Latham & Watkins LLP",
"SANTARUS ANNOUNCES LAUNCH OF A PROPOSED SECONDARY COMMON STOCK OFFERING BY A SELLING STOCKHOLDER",
"SANTARUS ANNOUNCES PRICING OF SECONDARY COMMON STOCK OFFERING BY A SELLING STOCKHOLDER"
05/10/2013 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
05/09/2013 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
05/06/2013 10-Q Quarterly Report for the period ended March 31, 2013
05/06/2013 8-K Quarterly results
Docs: "SANTARUS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Total revenues increase 73% with significant increase in net income over prior year period Raises 2013 financial outlook to include total revenues of $330 million to $340 million, net income of $57 million to $64 million and non-GAAP adjusted earnings of $81 million to $91 million"
05/03/2013 ARS Form ARS - Annual Report to Security Holders
04/26/2013 DEF 14A Form DEF 14A - Other definitive proxy statements
04/17/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "SANTARUS AND PHARMING ANNOUNCE SUBMISSION OF RUCONEST BIOLOGICS LICENSE APPLICATION TO FDA"
04/16/2013 8-K Other Events
04/12/2013 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy